mTOR Inhibitor Everolimus (Afinitor): MOA, Side effects, Dose
Novartis’ Afinitor (everolimus) was approved by the FDA on February 26, 2016, for the treatment of adult patients with unresectable, locally advanced or metastatic progressive, well-differentiated non-functional neuroendocrine tumors (NETs) originating from the gastrointestinal or lung areas. Afinitor, also known as everolimus, is a type of medication categorized as an mTOR inhibitor. It is available … Read more